MARKET

AVEO

AVEO

Aveo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.30
-0.10
-1.13%
Opening 13:04 03/03 EST
OPEN
8.33
PREV CLOSE
8.39
HIGH
8.59
LOW
8.05
VOLUME
255.36K
TURNOVER
--
52 WEEK HIGH
10.71
52 WEEK LOW
2.230
MARKET CAP
238.97M
P/E (TTM)
-5.3707
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
AVEO OncologytoPresent at the H.C. Wainwright Global Life Sciences Conference
AVEO Oncology (Nasdaq: AVEO) todayannounced that Michael Bailey, president and chief executive officer of AVEO, will present at the H.C. Wainwright Global...
BusinessWire - BZX · 1d ago
AVEO Oncology to Present at the H.C. Wainwright Global Life Sciences Conference
AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually on March 9-10, 2021.
BusinessWire · 1d ago
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
Most Food and Drug Administration decisions scheduled for February were positive, and more importantly five new molecular entities passed FDA muster.
Benzinga · 3d ago
Global Hepatocyte Growth Factor Market 2020 Research during the Ongoing COVID-19 Pandemic, Growth and Research Methodology by Forecast to 2025
CDN Newswire · 02/21 19:42
AVEO Oncology To Participate At SVB Leerink Global Healthcare Conference Feb. 25 At 3:00 p.m. ET
AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in a fireside chat at the 2021 SVB Leerink Global Healthcare Conference on Thursday,
Benzinga · 02/18 12:14
AVEO Oncology Announces Participation at the 2021 SVB Leerink Global Healthcare Conference
AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will participate in a fireside chat at the 2021 SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 3:00 p.m. Eastern Ti...
BusinessWire · 02/18 12:00
3 Top Biotech Stocks With Major Catalysts Approaching
TipRanks · 02/17 21:15
Relapsed Acute Myeloid Leukemia Drug Market 2021 Industry Manufactures Strategy Analysis, Share Estimation, Product Types, Applications, Trends and Forecast 2027
Feb 17, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” The global “Relapsed Acute Myeloid...
The Express Wire · 02/17 05:24
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AVEO. Analyze the recent business situations of Aveo through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AVEO stock price target is 12.00 with a high estimate of 17.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 139
Institutional Holdings: 12.02M
% Owned: 41.72%
Shares Outstanding: 28.81M
TypeInstitutionsShares
Increased
25
1.62M
New
25
-721.30K
Decreased
9
145.45K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.44%
Pharmaceuticals & Medical Research
-1.36%
Key Executives
President/Chief Executive Officer/Director
Michael Bailey
Chief Financial Officer
Erick Lucera
Other
Michael Needle
Lead Director/Independent Director
Kenneth Bate
Director
Corinne Epperly
Independent Director
Anthony Evnin
Independent Director
Gregory Mayes
Independent Director
Scarlett Spring
Independent Director
Robert Young
  • Dividends
  • Splits
  • Insider Activity
No Data
About AVEO
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).

Webull offers kinds of AVEO Pharmaceuticals, Inc. stock information, including NASDAQ:AVEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVEO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVEO stock methods without spending real money on the virtual paper trading platform.